Hepatitis C wonder-drug Sovaldi is still selling at breakneck pace. And at this rate, it could break some insurers. At $84,000 per 12-week treatment course, Sovaldi's quick uptake is threatening payers' earnings, analysts say–and the drug's stellar efficacy profile leaves them with few options.
written on 01.04.2014
Gilead's Sovaldi triumph puts major hurt on payers' bottom lines
